Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEXIMMUNE, INC.

(NEXI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

09/10/2021 | 09:11am EDT

GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference today, September 10, 2021 at 1:15p.m. Eastern time.

The webcast will be accessible on the Investor Relations page of NexImmune’s website at Events and Presentations | NexImmune, Inc. A replay of the presentation will be available at the same location for 30 days following the conference.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

For more information, visit www.neximmune.com.

Contacts

Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
646.319.3261
crubin@neximmune.com 


Primary Logo


© GlobeNewswire 2021
All news about NEXIMMUNE, INC.
09/27NEXIMMUNE : to Present at the 2021 Cantor Virtual Global Healthcare Conference
AQ
09/20NEXIMMUNE, INC.(NASDAQGM : NEXI) dropped from S&P Global BMI Index
CI
09/10NexImmune to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
GL
08/1115,079,875 Common Stock of NexImmune, Inc. are subject to a Lock-Up Agreement Ending on..
CI
08/11Certain Options of NexImmune, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-..
CI
08/09NEXIMMUNE : Management's Discussion and Analysis of Financial Condition and Results of Ope..
AQ
08/09Neximmune, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/09NEXIMMUNE, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure,..
AQ
08/09NEXIMMUNE : Reports Second Quarter 2021 Financial Results and Provides Business Updates
AQ
08/09NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabet..
GL
More news
Analyst Recommendations on NEXIMMUNE, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,86x
Yield 2021 -
Capitalization 291 M 291 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 44
Free-Float 72,6%
Chart NEXIMMUNE, INC.
Duration : Period :
NexImmune, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEXIMMUNE, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 12,88 $
Average target price 33,33 $
Spread / Average Target 159%
EPS Revisions
Managers and Directors
Scott Carmer President, Chief Executive Officer & Director
John Trainer Chief Financial Officer
Sol J. Barer Chairman
Jerome B. Zeldis Executive Vice President-Research & Development
Robert Knight Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NEXIMMUNE, INC.0.00%284
GILEAD SCIENCES, INC.14.98%83 830
BIONTECH SE251.28%65 071
WUXI APPTEC CO., LTD.25.77%64 894
REGENERON PHARMACEUTICALS17.86%58 504
VERTEX PHARMACEUTICALS-20.84%48 121